Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

A higher prostate cancer behavior score was associated with a 31% reduction in the hazard for all-cause mortality and a 33% ...

Cancer vaccines harness the power of the immune system to stop tumors in their tracks. They work a little differently than ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Records show that drug companies gave nearly $75,000 to the top Republican and Democrat on a committee investigating them.

A panel of scientific experts that advises the Food and Drug Administration on vaccine policy learned Wednesday that its upcoming meeting to discuss next year’s flu vaccines had been canceled.